Mode
Text Size
Log in / Sign up

SSRIs show significant reduction in depressive symptoms only when used for 6 months or longerSSRIs May Help Depression in Patients with Diabetes Over Time

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Note that SSRIs may only show significant antidepressant benefits in diabetic patients when used for 6 months or more.

This systematic review and meta-analysis evaluated the efficacy of SSRIs plus usual care compared to controls for patients with diabetes mellitus and comorbid depression. The study included 9 RCTs involving a total of 770 participants.

Regarding primary outcomes, no significant improvement in HDRS scores was observed overall (MD = 0.16; 95% CI -0.69 to 1.01). However, a significant reduction in HDRS scores was identified in the subgroup with follow-up durations of 6 months or more (MD = -0.96; 95% CI -1.86 to -0.05; P = 0.04). No significant improvement was observed for BDI scores. Conversely, SSRI use was associated with increased anxiety scores (HARS) (MD = 2.37; 95% CI 0.73 to 4.02; P = 0.005).

Secondary outcomes including HbA1c, FPG, PPG, and BMI showed no significant effects. The authors note that the evidence has low to moderate certainty. Clinically, SSRIs may provide modest antidepressant benefits in diabetic patients when used for at least 6 months, but they do not appear to improve glycaemic control or body mass index.

How this fits prior evidence

This meta-analysis addresses a gap in understanding pharmacological interventions for depression specifically within the diabetic population. While previous evidence has explored non-pharmacological interventions such as third-wave therapies, animal-assisted therapy, and mindfulness practice for various types of depression, this study focuses on SSRIs. It confirms that while SSRIs may improve depressive symptoms over longer durations (6 months), they do not impact metabolic markers like HbA1c or BMI in patients with diabetes.

This review looked at how certain antidepressants, known as SSRIs, affect patients who have both diabetes and depression. The study analyzed data from 770 participants across nine different clinical trials to see if these medications helped manage mood or blood sugar levels.

Researchers found that SSRIs did not show a significant improvement in depression scores for many patients overall. However, a notable difference was seen in the group of patients who took the medication for at least six months. In those cases, there was a measurable reduction in depressive symptoms. The study also noted that these medications were linked to a small increase in anxiety scores.

Regarding physical health markers like blood sugar control (HbA1c) and body mass index (BMI), no significant changes were found. Because the evidence is of low to moderate certainty, these results should be viewed as preliminary. Patients should talk to their doctor about how long they need to take a medication to see benefits.

What this means for you:
SSRIs may help depression in people with diabetes after 6 months of use, but they do not improve blood sugar levels.

Common questions

How long does it take for SSRIs to work for depression in people with diabetes?

The study found that while overall results were mixed, patients who took SSRIs for at least 6 months showed a significant reduction in depressive symptoms. This suggests that longer-term use may be more effective for managing mood in this specific group of patients.

Do these antidepressants affect blood sugar or weight?

The study found no significant effects on glycaemic control (HbA1c, FPG, PPG) or body mass index (BMI) for patients taking SSRIs. These medications do not appear to change how the body manages blood sugar levels in people with diabetes.

Can these medications cause other issues like anxiety?

The study reported that the use of SSRIs was associated with a small increase in anxiety scores. Because the evidence is of low to moderate certainty, you should discuss potential side effects and your specific treatment plan with your doctor.

Study Details

Study typeMeta analysis
EvidenceLevel 1
PublishedJul 2026
View Original Abstract ↓
ObjectivesTo evaluate the efficacy and safety of selective serotonin reuptake inhibitors (SSRIs) in patients with diabetes mellitus and comorbid depression.MethodsThis study was registered in PROSPERO (CRD420261305439). Eight electronic databases were searched up to February 11, 2026 for randomized controlled trials comparing SSRIs plus usual care versus control. Outcomes included depressive symptoms (HDRS, BDI), anxiety (HARS), glycaemic control (HbA1c, FPG, PPG), and BMI. Meta-analyses were performed using random-effects models; subgroup analysis by follow-up duration and sensitivity analysis were conducted.ResultsNine RCTs (770 participants) were included. Overall, SSRIs did not significantly improve HDRS (MD = 0.16, 95% CI -0.69 to 1.01, P = 0.72) or BDI scores. However, subgroup analysis showed significant HDRS reduction when follow-up was ≥ 6 months (MD = -0.96, 95% CI -1.86 to -0.05, P = 0.04). SSRIs were associated with increased HARS scores (MD = 2.37, 95% CI 0.73 to 4.02, P = 0.005). No significant effects were observed for HbA1c, FPG, PPG, or BMI.ConclusionPreliminary evidence suggests that SSRIs may offer modest antidepressant benefits when used for ≥ 6 months in diabetic patients with depression, but they may be associated with a small increase in anxiety scores and do not appear to improve glycaemic control or BMI. However, the overall certainty of evidence is low to moderate. Monitoring of early anxiety symptoms is recommended, and further high-quality RCTs are needed.Systematic Review Registrationhttps://www.crd.york.ac.uk/prospero/, identifier CRD420261305439.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.